“There was a sizeable drop in the total number of short positions at AC Immune SA throughout August (NASDAQ: ACIU). There were 375,700 shares available for a short sale as of August 31st, a fall of 18.6% from the temporary position of 461,300 shares the previous day. Roughly 0.9% of the total number of outstanding shares in the company are sold short at any given time. The number of days represented by short interest is currently 5.4. This is since each day, an average of 69,100 shares are traded.
On Thursday, July 28th, the most recent quarterly results report for AC Immune (NASDAQ: ACIU) was made available to the public. The company posted profits per share (EPS) for the quarter that were equal to the estimate made by the market, which was $0.24. This indicates that the market was satisfied with the company’s performance. According to forecasts made by analysts that follow the industry, AC Immune is expected to incur a loss of $1.01 per share during the current fiscal year, according to forecasts. The price of an ACIU on the previous Friday was 2.85 dollars. During the last year, the cost of AC Immune ranged from its all-time low of $2.06 to its all-time high of $8.14. There is a debt-to-equity ratio of 0.01, a quick ratio value of 13.28, a current ratio value of 13.28, and a short ratio value of 13.28.
The stock price has been trading at $3.21 on a moving average over the last 50 days, while the price has been $3.43 on a moving average basis over the previous 200 days. Over the past few months, several hedge funds have increased the percentage of the company’s shares they possess to a greater extent. During the first three months of 2018, Renaissance Technologies LLC increased its holdings of AC Immune stock by 2.3 percent. Renaissance Technologies LLC now owns a total of 452,490 shares, valued at $1,810,000, after purchasing an additional 10,300 shares during the past quarter. In the first three months of 2018, BlackRock Inc. boosted the percentage of AC Immune stock is owned by 1.6%.
BlackRock Inc. has increased its total holdings to 292,273 shares, valued at $1,170,000, following the acquisition of 4,685 additional company shares since the beginning of the most recent fiscal quarter. UBS Group AG’s interest in AC Immune rose by 191.2% during the second quarter due to the company’s investment. Following the purchase of an additional 36,000 shares during the quarter, UBS Group AG is now the owner of a total of 54,825 shares in the company. The current market price of these shares puts the entire worth of these holdings at a sum equal to $198,000. Handelsbanken Fonder AB made a new investment in AC Immune during the first three months of the year. The value of this transaction was a total of 404,000 Swedish Kronor. At the end of the year, during the fourth quarter, Metatron Capital SICAV plc invested $218,000 in AC Immune, establishing a new position in the company. At the moment, hedge funds and other institutional investors own 16.55 percent of the company’s total shares outstanding.
The Anti-Corruption and Integrity Unit (ACIU) has been the subject of inquiry in several recent studies. In a research report on the company published on Friday, June 17th, HC Wainwright reaffirmed a “buy” rating on shares of AC Immune and assigned a price objective of $16.00 in a research report on the company. In addition, the research report on the business stated that the price objective was set at $16.00. In a research report published on July 11th, SVB Leerink gave the company an “outperform” rating and lowered their target price on AC Immune from $15.00 to $10.00. In addition, the company evaluated the firm as “outperforming.” In addition, they bestowed the rating of “outperform” upon the business. StockNews.com did not start reporting on AC Immune until Monday, September 12th, when they published a research study regarding the firm.
They advised investors to “hold” onto the stock rather than sell it. Swiss-based biopharmaceutical company AC Immune SA is now in the trial stages of developing drugs and diagnostic tools to treat and prevent neurodegenerative disorders caused by protein misfolding. These illnesses include Alzheimer’s disease and Parkinson’s disease. By drawing on the capabilities of its SupraAntigen and Morphomer platforms, the company hopes to achieve its goal of developing vaccines, antibodies, and other small compounds that interact only with the misfolded proteins that are present in a wide variety of neurodegenerative illnesses. This will allow the company to meet its objective. “